Anti-SIGLEC15 / Sialic acid-binding Ig-like lectin 15

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. SIGLEC15 antibody recognizes Sialic acid-binding Ig-like lectin 15, a type I transmembrane protein belonging to the Siglec (sialic acid-binding immunoglobulin-like lectins) family of immune modulators. SIGLEC15 plays an important role in immune regulation, osteoclast differentiation, and tumor immune evasion. It binds sialylated glycoconjugates on target cells, transmitting inhibitory or activating signals that shape immune responses. The SIGLEC15 antibody is widely used in immunology, oncology, and bone biology research to study checkpoint signaling and macrophage-mediated immune regulation.Sialic acid-binding Ig-like lectin 15 is encoded by the SIGLEC15 gene located on human chromosome 18q12.3. The protein consists of an extracellular N-terminal V-set immunoglobulin domain that recognizes sialylated glycans, a transmembrane segment, and a short cytoplasmic tail that associates with adaptor proteins such as DAP12 or DAP10 to mediate downstream signaling. In osteoclasts, SIGLEC15 promotes differentiation and bone resorption by activating phosphoinositide 3-kinase and mitogen-activated protein kinase cascades. In immune cells, it functions as a checkpoint ligand that suppresses T-cell activation, analogous to PD-L1.Studies using the SIGLEC15 antibody have shown that this protein is upregulated on tumor-associated macrophages and osteoclasts in various malignancies and inflammatory diseases. Western blot analyses typically detect a 35-40 kilodalton glycoprotein band. Immunohistochemistry demonstrates strong membrane staining in macrophage-rich regions of tumors and in bone-resorptive zones. Functionally, SIGLEC15 acts as an immune suppressor by binding unidentified receptors on T cells and natural killer cells, inhibiting cytokine production and cytotoxic responses. Its expression inversely correlates with PD-L1, suggesting a complementary role in immune evasion mechanisms exploited by tumors.Therapeutic targeting of SIGLEC15 has emerged as a promising strategy in cancer immunotherapy, particularly for patients unresponsive to PD-1/PD-L1 blockade. The protein also regulates osteoclast activity and bone remodeling, making it relevant in osteoporosis and arthritis research. NSJ Bioreagents provides a validated SIGLEC15 antibody optimized for western blot, flow cytometry, and immunohistochemistry. This reagent enables researchers to investigate innate immune regulation, tumor microenvironment biology, and checkpoint-based immunotherapy development.